Workflow
微电生理收盘下跌1.49%,滚动市盈率178.68倍,总市值93.04亿元

Company Overview - Shanghai MicroPort EP MedTech Co., Ltd. focuses on the development, production, and sales of innovative medical devices in the field of electrophysiology interventional diagnosis and ablation treatment [2] - The company aims to provide globally competitive integrated solutions for diagnosis and ablation treatment centered on precise interventional navigation [2] Product Portfolio - Major products include the Columbus 3D cardiac electrophysiology mapping system, EasyFinder 3D magnetic positioning adjustable mapping catheter, and various disposable mapping and ablation catheters [2] - The company’s cryoablation devices and balloon-type cryoablation catheters have been approved for inclusion in the "2024 Shanghai Biomedical 'New Excellent Drugs and Devices' Product Directory" [2] - The fourth-generation 3D cardiac electrophysiology mapping system is also listed in the "2024 Shanghai Innovative Product Recommendation Directory" [2] Financial Performance - For the fiscal year 2024, the company reported revenue of 413 million yuan, representing a year-on-year increase of 25.51% [3] - Net profit reached 52.07 million yuan, showing a significant year-on-year growth of 815.36% [3] - The gross profit margin stood at 58.73% [3] Market Position - As of April 15, the company's stock closed at 19.77 yuan, with a rolling price-to-earnings (PE) ratio of 178.68, significantly higher than the industry average PE of 46.44 [1][3] - The total market capitalization is approximately 9.304 billion yuan [1] - The company ranks 113th in terms of PE ratio within the medical device industry [1] Institutional Holdings - As of the latest report, 187 institutions hold shares in the company, including 184 funds, with a total holding of approximately 74.29 million shares valued at 1.415 billion yuan [1]